1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma

New Protocol: Isatuximab – carfilzomib – dexamethasone for relapsed/refractory multiple myeloma
Study:
  • Randomized phase III study (IKEMA)
  • Relapsed/refractory multiple myeloma with >=2 prior lines including lenalidomide and a proteasome inhibitor
  • Isatuximab + carfilzomib + dexamethasone (n=179) vs. carfilzomid + dexamethasone (n=123)
Efficacy:
  • CRR: 39.7% vs. 27.6%
  • ORR: 86.6% vs. 82.9%
  • MRD negativity: 29.6% vs. 13.0% (p=0.0004)
  • Median PFS: NR vs. 19.1 mos (HR: 0.53 [0.32-0.89])
Safety:
  • Grade >=3 AEs: thrombocytopenia (30% vs. 24%), neutropenia (19% vs. 7%), infusion reactions (0.6% vs. 0%), respiratory infections (32% vs. 24%), cardiac failure (4% vs. 4%)

62nd ASH Annual Meeting. Dec 2020. Abstract 2316

Moreau P, et al. Isatuximab Plus Carfilzomib and Dexamethasone Vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-Label Study

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More